Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00766-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Padam Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Translational Health Sciences and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Mycobacterium bovis, Tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India (DBT).
Abstract (Originalsprache)
New drugs with novel mechanisms of action are urgently needed to tackle the issue of drug-resistant tuberculosis. Here, we have performed phenotypic screening using the Pathogen Box library obtained from the Medicines for Malaria Venture against Mycobacterium tuberculosis in vitro . We have identified a pyridine carboxamide derivative, MMV687254, as a promising hit. This molecule is specifically active against M. tuberculosis and Mycobacterium bovis Bacillus Calmette-Guérin ( M. bovis BCG) but inactive against Enterococcus faecalis , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumanii , Pseudomonas aeruginosa , and Escherichia coli pathogens. We demonstrate that MMV687254 inhibits M. tuberculosis growth in liquid cultures in a bacteriostatic manner. Surprisingly, MMV687254 was as active as isoniazid in macrophages and inhibited M. tuberculosis growth in a bactericidal manner. Mechanistic studies revealed that MMV687254 is a prodrug and that its anti-mycobacterial activity requires AmiC - dependent hydrolysis. We further demonstrate that MMV687254 inhibits M. tuberculosis growth in macrophages by inducing autophagy. In the present study, we have also carried out a detailed structure-activity relationship study and identified a promising novel lead candidate. The identified novel series of compounds also showed activity against drug-resistant M. bovis BCG and M. tuberculosis clinical strains. Finally, we demonstrate that in contrast to MMV687254, the lead molecule was able to inhibit M. tuberculosis growth in a chronic mouse model of infection. Taken together, we have identified a novel lead molecule with a dual mechanism of action that can be further optimized to design more potent anti-tubercular agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Health Sciences and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
- Department of Life Science, Laboratory of Mycobacterial Immunology, National Institute of Technology, Rourkela, India.
ORCID-Profile: Padam Singh, Dinesh Mahajan, Ramandeep Singh
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India (DBT)
Zitieren
APA
Singh, P., Kumar, A., Sharma, P., Chugh, S., Kumar, A., Sharma, N., Gupta, S., Singh, M., Kidwai, S., Sankar, J., Taneja, N., Kumar, Y., Dhiman, R., Mahajan, D., & Singh, R. (2024). Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00766-23
Vancouver
Singh P, Kumar A, Sharma P, Chugh S, Kumar A, Sharma N, et al. Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00766-23
BibTeX
@article{Singh2024,
author = {Singh, Padam and Kumar, Arun and Sharma, Pankaj and Chugh, Saurabh and Kumar, Ashish and Sharma, Nidhi and Gupta, Sonu and Singh, Manisha and Kidwai, Saqib and Sankar, Jishnu and Taneja, Neha and Kumar, Yashwant and Dhiman, Rohan and Mahajan, Dinesh and Singh, Ramandeep},
title = {Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00766-23}
}
EUVIMED